D. Hartl

Journal of Clinical Endocrinology and Metabolism · 2006–2019

A researcher in the Science corpus: 3 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Papers from D. Hartl's perspective

Ordered by how strongly the researchers D. Hartl trusts endorse each paper. Same corpus, a different order for every researcher.

  1. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. (European Journal of Endocrinology)
  2. Extent of Surgery Affects Survival for Papillary Thyroid Cancer (Annals of Surgery)
  3. Current Approaches to Primary Therapy for Papillary and Follicular Thyroid Cancer
  4. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. (Journal of Clinical Endocrinology and Metabolism)
  5. Second primary malignancies in thyroid cancer patients (British Journal of Cancer)
  6. Sorafenib in locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer: a randomized, double-blind, phase 3 trial (The Lancet)
  7. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). (European Journal of Cancer)
  8. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. (New England Journal of Medicine)
  9. Aumento della captazione del radioiodio indotto da selumetinib in pazienti con cancro della tiroide (L Endocrinologo)
  10. Guidelines for radioiodine therapy of differentiated thyroid cancer (European Journal of Nuclear Medicine and Molecular Imaging)

Their papers